Teos' Belrestotug shows efficacy in trials, backed by a strong cash runway. Learn why ITOS stock might thrive with strategic ...

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to a cancer drug called dostarlimab (brand name Jemperli) that has so far shown a 100 percent clinical ...

Spatial analysis of the immune microenvironment and identification of phenotypes of prognostic significance in penile squamous cell carcinoma (PSCC). World-wide oligometastatic prostate cancer (omPC) ...

Lurie Cancer Center initiates trial combining LIXTE's LB-100 and GSK's Dostarlimab for ovarian clear cell cancer treatment. LIXTE Biotechnology Holdings, Inc. has announced that the Robert H.

Lurie Cancer Center Completes Dosing of First Patient with LIXTE’s LB-100 in Combination with GSK’s Immunotherapy Dostarlimab --PASADENA, ...

The drugmaker remains convinced of the potential of the drug, however, and has just reported results of a trial comparing Jemperli (dostarlimab) to Merck & Co's market-leading Keytruda ...

In this transformative trial, 42 patients with mismatch repair-deficient (MMRd) or microsatellite instability-high (MSI) rectal tumors were treated with dostarlimab, an immunotherapy agent ...

A group of 18 colorectal cancer patients experienced complete remission after taking the experimental drug dostarlimab for six months. The trial conducted at Memorial Sloan Kettering Cancer Center ...

RUBY Part 2 tested Jemperli (dostarlimab) plus chemotherapy as initial treatment, followed by Jemperli and Zejula (niraparib) in combination as maintenance therapy, in patients with primary ...

“We are pleased to be participating in this important clinical trial to assess whether adding LIXTE’s LB-100 to GSK’s Dostarlimab will enhance the effectiveness of immunotherapy in the ...